A group of TSM1 mutant peptides and their applications

By replacing amino acids in the TSM1 peptide, a mutant with enhanced anticoagulation and anticomplement functions was designed, solving the disease problem caused by excessive activation of the complement system in the existing technology. It effectively inhibits complement C1q, C2, C3, C4, C5 and C6, protecting the body's health.

CN116589563BActive Publication Date: 2026-11-17HUBEI UNIV OF MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310606995.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2026-11-17
Estimated Expiration
2043-05-26

Smart Images

  • Figure CN116589563B_ABST
    Figure CN116589563B_ABST
Patent Text Reader

Abstract

This invention relates to a group of TSM1 mutant peptides and their applications, wherein the mutants are based on TSM1 peptides and the Y20 residues in their sequence are replaced with amino acids. This invention also relates to the pharmaceutical applications of the mutants, wherein the drugs are (1) for preparing anticoagulant drugs; and / or (2) for preparing anticomplement drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical biotechnology, specifically relating to a group of TSM1 mutant peptides and their applications. Background Technology

[0002] The complement system is an important component of the body's innate immune defense, including a series of heat-sensitive complement proteins that have enzymatic activity after activation, as well as their corresponding complement receptors and regulatory proteins[1]. It also serves as a bridge between the body's innate and adaptive immunity[2]. The complement activation process and the products formed by its activation can mediate a series of important biological effects such as cell lysis, opsonization, inflammatory response, and clearance of immune complexes. The complement system is a highly complex biological reaction system. Under physiological conditions, complement components in plasma are mostly inactive enzyme precursors, but after being activated by certain endogenous or exogenous substances, the complement system is activated through cascade enzyme reactions in different pathways. These pathways are divided into the classical pathway[3], the bypass pathway[4], the lectin pathway[5], and the properin pathway[6] and proteolytic pathway[7] discovered in recent years.

[0003] In some cases, excessive consumption or activation of complement is considered a major pathogenic factor in immune-mediated and inflammatory diseases. It can not only cause a large amount of complement to be consumed in vain, leading to a decrease in the body's ability to fight infection, but also cause a severe inflammatory response in the body and affect the coagulation and fibrinolytic system, thereby causing damage to normal tissue cells and leading to a variety of diseases such as systemic inflammatory response syndrome, sepsis, autoimmune diseases, age-related macular edema, kidney disease and transplant rejection [8-12].

[0004] Whether it's the complement system, the coagulation system, or the fibrinolytic system, their activation depends on a cascade of enzymatic reactions involving a series of serine proteases. Therefore, active peptide serine protease inhibitors have potential anti-complement and anticoagulant activities. We previously screened the Kunitz peptide TSM1 (patent number ZL201810463151.9) from tapeworms, which has both anticoagulant and anti-complement activities.

[0005] Accordingly, this application uses peptide TSM1 as a template, and based on the classification and property differences of the 20 amino acids that make up the protein, designs 10 peptide TSM1 derivatives, and conducts research on their preparation and evaluation of anticoagulation and anticomplement functions.

[0006] References

[0007] 1.MJ W:Complement.First of two parts.The New England Journal ofMedicine 2001,344(14):1058-1066.

[0008] 2.Ballanti E,Perricone C,Greco E,Ballanti M,Di Muzio G,Chimenti MS,Perricone R:Complement and autoimmunity.Immunologic research 2013,56(2-3):477-491.

[0009] 3.Botto M,Taylor PR,Carugati A,Fadok V,Cook HT,Andrews M,Carroll MC,Savill J,Henson P,Walport MJ:A hierarchical role for classical pathwaycomplement proteins in the clearance of apoptotic cells in vivo:A mechanismfor protection against autoimmunity.J Exp Med 2000,192(3):359-366.

[0010] 4.Camous L,Roumenina L,Bigot S:Complement alternative pathway acts asa positive feedback amplification of neutrophil activation.Blood 2011,117(4):1340-1349.

[0011] 5.Petersen SV,Thiel S,Jensen L:An assay for the mannan-binding lectinpathway of complement activation.Journal of Immunological Methods 2001,257:107-116.

[0012] 6.C.Morrison D,F.Kline L:Activation of the classical and properdinpathways of complement by bacterial lipopolysaccharides(LPS).The Journal ofImmunology 1977,118(1):362-368.

[0013] 7.Steffen Thiel,Thomas Vorup-Jensen,Cordula M.Stover:A second serineprotease associated with mannan-binding lectin that activatescomplement.Nature 1997,386(3):506-510.

[0014] 8.Sjoholm AG,Jonsson G,Braconier JH,Sturfelt G,Truedsson L:Complementdeficiency and disease:an update.Molecular immunology 2006,43(1-2):78-85.

[0015] 9.Das N,Biswas B,Khera R:Membrane-bound complement regulatoryproteins as biomarkers and potential therapeutic targets for SLE.Advances inexperimental medicine and biology 2013,735:55-81.

[0016] 10.Brodsky RA:Complement in hemolytic anemia.Blood 2015,126(22):385-391.

[0017] 11.McCaughan JA, O'Rourke DM, Courtney AE:The complement cascade inkidney disease:from sideline to center stage.American journal of kidneydiseases:the official journal of the National Kidney Foundation 2013,62(3):604-614.

[0018] 12.Vries Bd,Kohl J,Leclercq WKG:Complement factor C5a mediates renalischemia-reperfusion injury independent from neutrophils.Journal ofimmunology 2003,170(7):3883-3889.

[0019] 13. Brealey D, Karyampudi S, Jacques TS, Novelli M, Stidwill R, Taylor V, Smolenski RT, Singer M: Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004, 286(3): R491-497. Summary of the Invention

[0020] This invention first relates to a group of mutants of the TSM1 peptide, wherein the mutants are based on the TSM1 peptide and the Y20 residue in its sequence is replaced with amino acids. Specifically, the mutants are: Y20S, Y20K, Y20D, Y20G, Y20H, Y20L, Y20M, Y20N, Y20W, and Y20V.

[0021] The amino acid sequence of the TSM1 polypeptide is as follows:

[0022] KMSYINRCNLPISSGQCRGYFLRYGYDSEADECRRFVYSGCRGNRNNFFTYNECMNRCYMRFK.

[0023] The present invention also relates to the nucleotide sequence encoding a mutant of the TSM1 polypeptide described herein.

[0024] This invention also relates to the following uses of mutants of the TSM1 polypeptide,

[0025] (1) Preparation of anticoagulant drugs;

[0026] (2) Preparation of anticomplement drugs.

[0027] Preferably, the anticoagulant is a drug that inhibits intrinsic coagulation, and the intrinsic coagulation pathway refers to prolonging the activated partial thromboplastin time (APTT).

[0028] Preferably, the anticomplement drug is a drug that inhibits complement C1q, C2, C3, C4, C5 and / or C6.

[0029] Preferably, the anticomplement drug is used to prevent and / or treat sepsis caused by excessive complement activation.

[0030] The beneficial effect of this invention is that, based on previous work, mutation screening of the TMS1 peptide was carried out, and mutants with stronger biological activity were obtained. Attached Figure Description

[0031] Figure 1 SDS-PAGE identification of TSM1 mutant peptides

[0032] Lane 1A, Lane 1 is protein marker, Lane 2 is TSM1, Lane 3 is TSM1Y20S, Lane 4 is TSM1Y20, Lane 5 is TSM1Y20D, Lane 6 is TSM1Y20G, Lane 7 is TSM1Y20H;

[0033] Lane 1B, Lane 1 is protein marker, Lane 2 is TSM1, Lane 3 is TSM1Y20L, Lane 4 is TSM1Y20M, Lane 5 is TSM1Y20N, Lane 6 is TSM1Y20W, and Lane 7 is TSM1Y20V.

[0034] Figure 2 Evaluation of the anticoagulant function of the TSM1 mutant peptide.

[0035] Figures 2A, 2B, and 2C show the APTT, PT, and TT measurements of the peptide, respectively. The X-axis represents the final concentration of the peptide. The Y-axis represents the ratio of APTT, PT, and TT times between the peptide group and the negative control group (PBS group).

[0036] Figure 3Evaluation of the anti-complement function of the TSM1 mutant peptide: The X-axis represents different peptides at a final concentration of 10 μM. The Y-axis represents the inhibition rate of complement by the peptides. The negative control was GVB buffer, and the positive control was ultrapure water.

[0037] Figure 4 The concentration-dependent evaluation of complement resistance of the TSM1 mutant peptide was performed. The X-axis represents different concentrations of the peptide, namely 0, 2.5 μM, 5 μM, 7.5 μM, 10 μM, 15 μM, and 20 μM; the Y-axis represents the complement inhibition rate of the peptide.

[0038] Figure 5 The anticomplement mechanism of the anticomplement peptide TSM1Y20G

[0039] 5A represents the hemolysis rate of sensitized sheep erythrocytes after incubation of TSM1Y20G with complement followed by replenishment of missing serum.

[0040] 5B represents the inhibition rate of TSM1Y20G against different complement targets.

[0041] Figure 6 Survival curves of peptide TSM1Y20G against LPS-induced severe sepsis in mice.

[0042] The X-axis represents the observation time, and the Y-axis represents the mouse survival rate. Detailed Implementation

[0043] Example 1: Molecular design and preparation of TSM1 mutant peptide

[0044] Specifically, using the TSM1 peptide as a template, amino acid substitutions were performed on the Y20 residue in its sequence, resulting in a total of 10 mutants: TSM1Y20S, TSM1Y20K, TSM1Y20D, TSM1Y20G, TSM1Y20H, TSM1Y20L, TSM1Y20M, TSM1Y20N, TSM1Y20W, and TSM1Y20V.

[0045] The amino acid sequence of the TSM1 polypeptide is as follows:

[0046] KMSYINRCNLPISSGQCRG Y FLRYGYDSEADECRRFVYSGCRGNRNNFFTYNECMNRCYMRFK

[0047] Recombinant plasmids containing the target sequence were prepared and transformed into DE3 to obtain expression bacteria, using a similar method to that used for TSM1 peptide. Generally, successfully transformed bacterial cultures were activated in 3% Kana LB liquid medium, expanded, and then induced with IPTG (final concentration 1 mM) for 4 hours. The induced bacterial culture was centrifuged, the supernatant was discarded, and the precipitate was resuspended in ice-cold PBS. After sonication to disrupt the cell wall, the supernatant was discarded, the precipitate was washed twice with ice-cold PBST, centrifuged again, and resuspended in 0.03 g / mL reduced glutathione denaturing buffer for 2 hours at room temperature. The supernatant after high-speed centrifugation was slowly renatured at 16°C in renaturing buffer containing 0.012 g / mL oxidized glutathione. The renaturing buffer was concentrated and desalted using ultrafiltration, purified by RP-HPLC, and the purified protein solution was freeze-dried into a powder and subjected to quality testing (SDS-PAGE gel electrophoresis is shown in [link to SDS-PAGE gel electrophoresis]). Figure 1 ) and packaging.

[0048] Example 2: Anticoagulant function of the TSM1 mutant peptide

[0049] (I) Evaluation of the anticoagulant function of peptides

[0050] APTT function assay of peptides:

[0051] 1. Turn on the TSA9000C coagulation analyzer and preheat an appropriate amount of APTT reagent and Cacl2 reagent;

[0052] 2. Add 25 μL of different concentrations of peptide, negative control (ddH2O) and positive control (final concentration of heparin is 2.14 μg / mL) to a 1 mL EP tube in sequence, and 50 μL of healthy human plasma. Incubate at room temperature for 15 minutes. During incubation, enter the sample information and APTT test items.

[0053] 3. Place the EP tube into the sample position on the instrument. During the detection, the instrument will automatically add 50 μL of APTT reagent and 50 μL of Cacl2 reagent.

[0054] 4. Import the data into an Excel spreadsheet and use the graphing software Prism to create a graph.

[0055] PT function detection of peptides:

[0056] 1. Turn on the TSA9000C coagulation analyzer and preheat an appropriate amount of PT reagent;

[0057] 2. Add 25 μL of different concentrations of peptide, negative control (ddH2O) and positive control (final concentration of heparin is 2.14 μg / mL) to a 1 mL EP tube in sequence, and 50 μL of healthy human plasma. Incubate at room temperature for 15 minutes. During incubation, enter the sample information and PT detection items.

[0058] 3. Place the EP tube into the sample position on the instrument. During the detection, the instrument will automatically add 100 μL of APTT reagent.

[0059] 4. Import the data into an Excel spreadsheet and use the graphing software Prism to create a graph.

[0060] TT function assay of peptides:

[0061] 1. Turn on the TSA9000C coagulation analyzer and preheat an appropriate amount of TT reagent;

[0062] 2. Add 25 μL of different concentrations of peptide, negative control (ddH2O) and positive control (final concentration of heparin is 2.14 μg / mL) to a 1 mL EP tube in sequence, and 100 μL of healthy human plasma. Incubate at room temperature for 15 minutes. During incubation, enter the sample information and PT detection items.

[0063] 3. Place the EP tube into the sample position on the instrument. During the detection, the instrument will automatically add 100 μL of APTT reagent.

[0064] 4. Import the data into an Excel spreadsheet and use the graphing software Prism to create a graph.

[0065] The results show ( Figure 2 The mutant TSM1 has an inhibitory effect on the intrinsic coagulation pathway, and its APTT time prolongation fold is not significantly different from that of wild-type TSM1. It has no inhibitory effect on the extrinsic coagulation pathway (PT) and the common coagulation pathway.

[0066] Example 3: Evaluation of the anticomplement function of the peptide

[0067] In this experiment, rabbit anti-sheep serum was used as a hemolysin to sensitize sheep red blood cells. Sensitized sheep red blood cells can activate the classical complement pathway under the conditions of Ca2+ and Mg2+, thereby causing hemolysis of sheep red blood cells. The degree of hemolysis is directly proportional to the complement content.

[0068] (I) Determination of complement potency

[0069] 1. Collect serum (NHS) from 10 healthy volunteers as complement, mix well, aliquot, and store at -80℃.

[0070] 2. Mix 500 μL of sheep red blood cell suspension with 1 mL of ice-cold GVB buffer, centrifuge at 1000 rpm for 10 minutes at 4°C, discard the supernatant, and wash three times. Add 20 μL of the red blood cell pellet to 980 μL of ice-cold GVB buffer to prepare 2% sheep red blood cells.

[0071] 3. Preparation of sensitized sheep red blood cells (EA): Rabbit anti-sheep serum was diluted with GVB buffer to a ratio of 1:1000 as a hemolysin, and then incubated with an equal volume of 2% sheep red blood cells (SRBC) at 37°C for 30 minutes to complete the sensitization of SRBC.

[0072] 4. Complement (NHS) was diluted with GVB at ratios of 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, and 1:640. The components were added according to Table 1. The solutions were incubated in a 37°C water bath for 30 minutes, then centrifuged at 5000 rpm for 10 minutes at 4°C. 200 μL of the supernatant from each tube was transferred to a 96-well plate, and the absorbance was measured at 405 nm. The absorbance of the ultrapure water-soluble blood vessel was used as the standard for complete hemolysis, and the hemolysis rate was calculated.

[0073] Table 1. Volumes (μL) of each component added for complement potency determination

[0074]

[0075] Plot the complement dilution factor on the X-axis and the hemolysis rate caused by complement at each dilution factor on the Y-axis. Select the lowest complement concentration that can cause near-total lysis of sensitized sheep red blood cells (in this experiment, it was a 1:20 dilution of serum) as the critical complement concentration required to ensure the system.

[0076] (II) Determination of Anticomplement Activity via Classical Peptide Pathway

[0077] 1. Mix equal volumes of critical concentration NHS and 10 μM peptide, incubate at 37°C for 10 minutes.

[0078] 2. Add EA and GVB according to Table 2, incubate in a 37°C water bath for 30 minutes, then centrifuge at 4°C and 5000 rpm for 10 minutes. Take 200 μL of the supernatant from each tube into a 96-well plate and measure the absorbance at 405 nm.

[0079] 3. Plot a graph with the peptide as the X-axis and the hemolysis inhibition rate as the Y-axis. The experiment also included complement, total lysis, and GVB groups.

[0080] Table 2. Volumes (μL) of each component added in the classic route anticomplement hemolysis test

[0081]

[0082] Complement inhibition rate of the peptide = (A405 complement group - A405 peptide group) / (A405 complement group - A405 GVB group) × 100%

[0083] 4. Take critical concentration NHS and mix it with equal volumes of 0μM, 2.5μM, 5μM, 7.5μM, 10μM, 15μM and 20μM peptides. Incubate at 37℃ for 10 minutes. Add EA and GVB. Incubate at 37℃ for 30 minutes. Centrifuge at 4℃ and 5000rpm for 10 minutes.

[0084] 5. Take 200 μL of supernatant from each tube into a 96-well plate and measure the absorbance at 405 nm.

[0085] 6. Plot a graph with the polypeptide as the X-axis and the hemolysis inhibition rate as the Y-axis.

[0086] The experiment included complement group, total dissolution group, and GVB group.

[0087] The results are as follows Figure 3 As shown, the anti-complement activity of the TSM1 mutant was increased compared with that of the wild-type TSM1. Figure 5 ),

[0088] (III) Detection of the inhibitory effect of different concentrations of peptides on complement

[0089] A peptide that exhibited a complement inhibition rate of over 85% at a final concentration of 10 μM was selected. The inhibitory effects of different concentrations of the peptide on complement were investigated. The results showed that...

[0090] (1) All polypeptide groups showed concentration-dependent inhibitory activity against complement. Figure 4 The IC50 values ​​for each polypeptide inhibiting complement are as follows:

[0091] Peptide TSM1Y20S, 2.693 + 0.050 μM

[0092] TSM1Y20SK, 2.028 + 0.065μM

[0093] TSM1Y20SG, 1.710+0.580μM

[0094] TSM1Y20H, 2.913 + 0.181 μM

[0095] TSM1Y20SL, 6.023 + 0.444 μM

[0096] TSM1Y20SM, 4.885+0.9798μM.

[0097] It can be seen that the anti-complement activity of TSM1Y20G is significantly enhanced compared to TSM1.

[0098] Example 4: Study on the anti-complement mechanism of the peptide TSM1Y20G mutant

[0099] (I) Preparation of serum lacking complement C1q, C3, and C4 components

[0100] 1. Dilute the purchased anticomplement C1q, C3, and C4 antiserum to different concentrations and mix with an equal volume of 1:20 NHS. Incubate for 15 minutes, centrifuge, and take the supernatant for hemolysis experiment.

[0101] 2. The experimental results showed that the anti-complement C1q, C3 and C4 components of antiserum inhibited hemolysis of sensitized sheep erythrocytes by nearly 100% at dilution ratios of 1:152, 1:64 and 1:32, respectively, which can be regarded as the critical concentration for inhibiting complement C1q, C3 and C4 components in 1:20 NHS.

[0102] Therefore, antisera containing complement components C1q, C3, and C4 at dilution ratios of 1:152, 1:64, and 1:32 were mixed with 1:20 NHS and incubated. After centrifugation, the supernatant was collected to obtain serum lacking C1q, C3, and C4 components. Human serum lacking complement components C2, C5, C6, C7, and C8 was a commercially available product, diluted 40-fold with GVB before use.

[0103] (II) Complement Deficiency Test

[0104] The maximum complement inhibition rate was achieved at a TSM1Y20G concentration of 15 μM. Therefore, 15 μM TSM1Y20G was selected for complement deficiency experiments.

[0105] 1. After incubating 15 μM TSM1Y20G with 1:20 NHS for 10 min, the non-replenishment group was replenished with GVB buffer, and the missing group was replenished with serum containing missing C1q, C2, C3, C4, C5, C6, C7, and C8 components.

[0106] 2. If TSM1Y20G acts on the missing complement component, hemolysis will not occur; otherwise, hemolysis will occur.

[0107] GVB buffer was used as a negative control. The greater the difference between the peptide group and the negative control group, the stronger the inhibitory effect of TSM1Y20G on complement components. The results showed that TSM1Y20G inhibited C1q, C2, C3, C4, C5, and C6. Figure 5 ).

[0108] Example 5: Protective effect of the TSM1Y20G mutant against LPS-induced severe sepsis in mice.

[0109] 1. C57BL / 6 mice were injected intraperitoneally with 20 mg / kg of LPS. The mice showed obvious piloerection, increased secretions in the corners of their eyes, loose stools, obvious abdominal swelling, significantly decreased alertness, no response to the surrounding environment, and basically no movement. According to the Singer, M.

[13] criteria, intraperitoneal injection of 20 mg / kg of LPS can induce severe sepsis in mice.

[0110] 2. After successful model construction, TSM1Y20G, which showed significantly enhanced anti-complement activity, was selected to evaluate the protective effect of the peptide on mice. First, mouse survival rate analysis was performed. The experiment was divided into three groups, with 12 mice in each group: control group (Saline group), model group (Saline + LPS), and treatment group (LPS + TSM1Y20G).

[0111] The model group received an intraperitoneal injection of Saline 1 hour before LPS injection;

[0112] One hour before the LPS (20 mg / kg) injection, the treatment group received an intraperitoneal injection of TSM1Y20G (40 mg / kg).

[0113] The control group did not receive LPS injections, but received an equal amount of Saline intraperitoneally.

[0114] After a 7-day observation period, the survival rate of mice in the treatment group was 100%, while all mice in the model group died within two days. This indicates that the peptide TSM1Y20G has a protective effect against sepsis in mice. Figure 6 ).

[0115] Finally, it should be noted that the above embodiments are only used to help those skilled in the art understand the essence of the present invention, and are not intended to limit the scope of protection of the present invention.

Claims

1. A mutant of a TSM1 polypeptide, wherein the mutant is obtained by replacing the Y20 residue in the sequence of a TSM1 polypeptide with an amino acid substitution selected from the group consisting of Y20S, Y20K, Y20G, Y20H, Y20L and Y20M, and wherein the amino acid sequence of the TSM1 polypeptide is KMSYINRCNLPISSGQCRGYFLRYGYDSEADECRRFVYSGCRGNRNNFFTYNECMNRCYMRFK.

2. A nucleotide encoding the mutant of the TSM1 polypeptide of claim 1.

3. Use of the mutant of claim 1 or the nucleotide of claim 2 in the manufacture of a medicament for preventing and / or treating sepsis due to over-activation of complement.

Citation Information

Patent Citations

  • TSM1 peptide and its application in the preparation of anticomplement drugs

    CN108586605B

  • Scorpion venom polypeptide for inhibiting complement and mutant of scorpion venom polypeptide

    CN112175060A

  • Set of parasitic tapeworm polypeptides for inhibiting complement

    CN112206310A